Rosetta Genomics (Rehovot, Israel) is working to develop the second-generation miRview mets, a test for cancer of unknown primary. The current version of this test has a tumor panel of 25 cancers. The company is designing a test to identify a much larger panel of cancer origins, which it expects to market by the second half of 2010.

After differentiating small-cell lung cancer from non-small-cell lung cancer, a test will further subclassify non-small-cell lung cancer into squamous or nonsquamous. This test is being developed to leverage the company's new Fine Needle Aspirate (FNA) platform technology across several types of tests. The company aims to launch the extended lung cancer diagnostic in the second half of 2011.

The third test being developed by Rosetta Genomics is for bladder cancer. The aim of this test is to predict the risk of superficial bladder cancer becoming invasive. The target date for commercialization is late 2011.

Rosetta Genomics is a developer of microRNA-based molecular diagnostics. Its integrative research platform, combining bioinformatics and state-of-the-art laboratory processes, has led to the discovery of hundreds of biologically validated novel human microRNAs. The company is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools.

Related Links:
Rosetta Genomics